The global breast cancer market size accounted for USD 34.63 billion in 2024, grew to USD 38.06 billion in 2025 and is predicted to surpass around USD 89.01 billion by 2034, representing a healthy CAGR of 9.90% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Breast Cancer Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Breast Cancer Market, by Therapy, 2024-2034
8.1.1 Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Hormonal Therapy
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Surgery and radiation therapy
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Biologic therapy
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Breast Cancer Market, by Cancer Type, 2024-2034
9.1.1. Hormone Receptor
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. HER2+
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Breast Cancer Market, by Distribution Channel, 2024-2034
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.1.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Therapy (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1. Merck & Co
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol Myers Squiib
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Kyowa Kirin
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Eisai Co.Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sanofi
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer Inc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. AstraZeneca
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Eli Lilly and Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Genentech
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample